Pneumonia Pathology — Lobar, Broncho, Interstitial

Aspiration and Mucosal Colonization

• Disruption of normal host defenses (impaired cough reflex, decreased mucociliary clearance, altered swallowing) allows pathogenic organisms to colonize and adhere to respiratory epithelium via bacterial adhesins (pili, fimbriae, lipopolysaccharides)
• Commensal flora overgrowth or exogenous pathogen inoculation initiates the inflammatory cascade
• Bacterial virulence factors (toxins, superantigens, proteases) directly damage epithelial barrier integrity

Innate Immune Activation and Complement Cascade

• Recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (TLRs, NOD-like receptors) on macrophages and epithelial cells triggers rapid NF-κB signaling and MAPK activation
• Complement activation (typically via alternative pathway with gram-negative organisms, classical pathway with gram-positive) generates C3a and C5a chemotactic factors
• Tissue factor (TF) upregulation on monocytes and endothelial cells initiates the extrinsic coagulation pathway, promoting fibrin deposition in alveolar spaces

Neutrophil Recruitment and Acute Phase Response

• Chemokine gradients (IL-8, TNF-α, MCP-1) established by infected macrophages recruit and activate neutrophils via CXCR1/CXCR2 and CCR2
• Neutrophils migrate through endothelial barriers via ICAM-1/LFA-1 interactions, causing transient increased vascular permeability
• Neutrophilic inflammation produces reactive oxygen species (ROS) and proteases (elastase, collagenase) that damage both pathogens and host tissue, contributing to epithelial injury and fibrinolysis
• Acute phase proteins (C-reactive protein, serum amyloid A) produced by hepatocytes amplify inflammatory signals and promote bacterial opsonization

Morphological Patterns Reflect Anatomic Localization and Immune Response

Lobar Pneumonia (Classically Streptococcus pneumoniae)

• Typically aerobic gram-positive cocci with rapid replication and toxin production trigger robust neutrophilic response
• Infection spreads rapidly across pores of Kohn (interalveolar communications) and canals of Lambert (communicating channels between terminal and respiratory bronchioles), causing homogeneous consolidation of entire lobes or segments
• The four classic stages correlate with histological evolution:

1. 1.Congestion (0-24 hrs): Minimal pneumocyte injury; alveolar edema with erythrocytes and scant organisms; lung appears heavy and dark red
2. 2.Red hepatization (1-3 days): Massive neutrophilic infiltration transforms lung to liver-like consolidation; fibrin deposition increases; alveolar architecture preserved
3. 3.Gray hepatization (3-8 days): Neutrophil lysis releases enzymes; fibrin becomes increasingly prominent and organized; cellular debris accumulates; red appearance fades to gray-tan
4. 4.Resolution (8-10+ days): Macrophage-mediated fibrinolysis; bacteria killed; return to normal architecture (or occasionally fibrosis if severe)

Bronchopneumonia (Mixed flora, gram-negative rods, S. aureus)

• Polymicrobial infections or organisms with reduced virulence cause patchy, multifocal consolidation centered around terminal and respiratory bronchioles
• Inflammation spreads along bronchiolar airways (bronchitis) with secondary alveolar involvement, creating peribronchial infiltrates visible histologically
• Pattern reflects centripetal spread from airways rather than centrifugal spread across pores
• More common in debilitated, elderly, or hospitalized patients with impaired airway clearance

Interstitial (Atypical) Pneumonia (Viruses, Mycoplasma, Legionella, Pneumocystis)

• Cytokine-driven inflammation (IFN-γ, IL-2 from T cells) preferentially involves alveolar septa with lymphocyte and plasma cell infiltration rather than acute neutrophilic response
• Pathogens may directly infect respiratory epithelial cells (viral tropism) or persist within macrophages (Legionella, mycobacteria)
• Minimal alveolar space exudation initially; characteristic mononuclear infiltrate of alveolar walls
• Alveolar lining cells (pneumocytes) undergo hyperplasia and occasional detachment, leading to denuded basement membranes; some organisms (RSV, paramyxoviruses) produce giant cells and syncytia from multinucleated pneumocyte fusion
• May progress to diffuse alveolar damage (DAD) with hyaline membrane formation if severe

Bacterial Virulence Mechanisms Determine Severity

• Polysaccharide capsule of S. pneumoniae and H. influenzae resists opsonization and complement-mediated lysis; serotype determines invasiveness
• Lipopolysaccharide (LPS/endotoxin) of gram-negative rods (especially Pseudomonas, E. coli) activates TLR4/MD-2 complex, triggering systemic inflammation and potential sepsis/ARDS progression
• Superantigens (streptococcal pyrogenic exotoxins, S. aureus enterotoxins) bypass normal antigen presentation, causing massive polyclonal T-cell activation and cytokine release

Community-Acquired Pneumonia (CAP) — Most Common Organisms

• Streptococcus pneumoniae (most common bacterial CAP overall; classic lobar pattern)
• Haemophilus influenzae type b (now less common post-vaccine; bronchopneumonia pattern)
• Atypical organisms — Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila (interstitial pattern; often with systemic symptoms)
• Viruses — Influenza A/B, RSV, parainfluenza, rhinovirus, coronavirus, adenovirus (interstitial; often prodromal URI symptoms)
• Streptococcus pyogenes (Group A; post-influenza; toxin-mediated severe disease)
• Moraxella catarrhalis (gram-negative diplococcus; typically mild, comorbid patients)
• Anaerobes (from aspiration; Peptostreptococcus, Prevotella, Fusobacterium)
• Fungi (in endemic regions or immunocompromised: Histoplasma, Coccidioides, Blastomyces)

Healthcare-Associated Pneumonia (HCAP) / Hospital-Acquired Pneumonia (HAP) — Gram-Negative Rods and *S. aureus

• Pseudomonas aeruginosa (high mortality; biofilm production; innate resistance to antibiotics)
• Klebsiella pneumoniae (often ESBL-producing; hypervirulent strains in diabetics)
• E. coli, other Enterobacteriaceae
• Staphylococcus aureus (including MRSA; rapid tissue destruction; abscess formation)
• Acinetobacter baumannii (multidrug-resistant; ICU populations)

Immunocompromised Hosts — Opportunistic Pathogens

• Pneumocystis jirovecii pneumonia (PCP) in HIV/AIDS (CD4 <200): foamy, eosinophilic alveolar exudate with cup-shaped organisms on GMS stain; interstitial inflammation
• Cytomegalovirus (CMV): direct viral cytopathic effect; "owl's eye" inclusion bodies (intranuclear) in pneumocytes and endothelial cells
• Mycobacterium tuberculosis (cavitary or non-cavitary; apical-posterior lobes; caseating granulomas)
• Mycobacterium avium complex (MAC) in advanced AIDS
• Fungal infections: Cryptococcus neoformans, Aspergillus (angioinvasion; tissue infarction), Candida (rare primary; usually aspiration risk)
• Toxoplasma (CNS predilection; can cause disseminated pneumonia)

Risk Factors

Host-Related Factors

• Age extremes: infants (<1 year, immature immune system) and elderly (>65 years, immune senescence, comorbidities)
• Chronic lung disease: COPD (impaired mucociliary clearance), asthma (bronchial hyperresponsiveness), cystic fibrosis (mucus plugging), bronchiectasis (airway stasis)
• Cardiovascular disease: heart failure (pulmonary edema + bacteria), recent MI (aspiration risk)
• Diabetes mellitus (hyperglycemia impairs neutrophil function; hypervirulent K. pneumoniae)
• Renal/hepatic disease: uremia and cirrhosis impair immunoglobulin synthesis and complement
• Immunosuppression: HIV/AIDS (CD4 count), chemotherapy, transplantation (calcineurin inhibitors, mTOR inhibitors), biologics (TNF inhibitors increase TB/fungal risk)
• Smoking (ciliary dysfunction, impaired macrophage function, increased colonization)
• Alcoholism (aspiration, impaired granulocyte function, malnutrition)
• Obesity: impaired immune function, aspiration risk

Environmental/Behavioral Factors

• Aspiration risk: impaired swallowing (stroke, myasthenia gravis, dysphagia), altered consciousness (alcohol, seizures, anesthesia, sedation), nasogastric tubes, supine positioning
• Recent antibiotic use (selective pressure for resistant organisms in HAP)
• Hospitalization/ICU admission (nosocomial pathogens, ventilator-associated pneumonia)
• Travel history: endemic fungi (southwest USA for Coccidioides, Ohio/Mississippi valleys for Histoplasma)
• Animal exposure: Psittacosis (parrots, Chlamydia psittaci), Q fever (Coxiella burnetii, cattle/sheep)
• Water exposure: Legionella (cooling towers, hot tubs, improperly chlorinated water)

Lobar Pneumonia (Typical/Classic Presentation)

• Acute onset (24-48 hours): sudden high fever (>39°C), shaking chills (rigors from endotoxin/cytokine surge), malaise
• Productive cough with purulent sputum ("rusty" sputum in S. pneumoniae — due to blood-tinged fibrinous exudate); hemoptysis occasionally
• Pleuritic chest pain (worse with deep inspiration/cough) — reflects pleural inflammation from adjacent consolidation or frank parapneumonic effusion
• Dyspnea: tachypnea (20-40 breaths/min) reflecting hypoxemia from ventilation-perfusion (V/Q) mismatch (consolidated lung poorly ventilated but still perfused) and decreased diffusion capacity
• Physical examination findings:
• Dullness to percussion over consolidated lobe (fluid-filled lung transmits percussion vibrations poorly)
• Bronchial breath sounds (high-pitched tubular sounds; consolidated lung conducts sound from central airways directly to chest wall) and egophony ("e" sounds like "a" through stethoscope; increased transmission of vocal resonance through consolidated tissue)
• Tactile fremitus increased (consolidated lung transmits vibrations; contrast with pneumothorax where decreased)
• Fine crackles (rales) — opening of small airways filled with exudate during inspiration
• Cyanosis (if severe hypoxemia)
• Lab findings: Leukocytosis (WBC 15,000-40,000) with left shift (increased bands/immature forms) reflecting acute bacterial stimulus; elevated inflammatory markers (ESR, CRP); hyponatremia (SIADH from cytokine effect); mild hyperbilirubinemia (hepatocellular injury from inflammation)
• Chest X-ray pattern: Homogeneous consolidation respecting lobar/segmental boundaries (lobar pneumonia often right lower lobe in S. pneumoniae); air bronchograms present (bronchi visible as dark lines within consolidation, pathognomonic for alveolar filling); may progress through sequential radiographic stages paralleling histology

Bronchopneumonia (Indolent Onset)

• Insidious onset over several days, often following URI or aspiration event
• Chronic cough ± sputum; fever often low-grade or absent initially
• Dyspnea less prominent than lobar pneumonia initially; respiratory distress develops if progression
• Physical exam: Patchy crackles over multiple lung fields (not confined to one lobe); bronchial breath sounds less prominent; no clear lobar consolidation
• Chest X-ray: Patchy, bilateral infiltrates in peribronchial distribution (especially lower lung bases); no clear lobar consolidation; may see air bronchograms but often less prominent
• Often seen in elderly, bedridden patients; higher risk of aspiration and polymicrobial infection
• May progress to sepsis if organism (e.g., MRSA, P. aeruginosa) highly virulent or host severely immunocompromised

Interstitial (Atypical) Pneumonia

• Gradual onset (2-7 days): nonproductive or minimally productive cough, low-grade fever (often ≤39°C), malaise/myalgias (systemic symptoms predominate)
• Prodrome common: URI symptoms (rhinitis, pharyngitis, otitis) preceding pneumonia by days, especially viral pneumonia and Mycoplasma
• Extrapulmonary manifestations:
• Mycoplasma: rash (occasionally erythema multiforme), otitis, myringitis (hemorrhagic bullae on tympanum), arthritis/arthralgia
• Legionella: GI symptoms (diarrhea, nausea), CNS findings (confusion, headache, hyponatremia — SIADH very common), renal dysfunction
• Viral (influenza): severe myalgias, headache, generalized malaise often worse than respiratory symptoms
• Dyspnea often disproportionate to physical exam findings and initial X-ray severity (hallmark of interstitial process)
• Physical examination: often unremarkable; may hear only fine crackles at lung bases; no consolidation on percussion or auscultation
• Chest X-ray: Bilateral, interstitial infiltrates (linear or reticular pattern); bilateral lower lobe predominance; no consolidation or air bronchograms initially (contrast with lobar/bronchopneumonia); may have perihilar distribution ("butterfly" pattern in severe cases)
• Lab: Mild to moderate leukocytosis (or

Step 1 — establish that an infiltrate exists

• Chest radiograph (PA and lateral): the initial and effectively required test; the 2019 ATS/IDSA CAP guideline defines pneumonia as compatible symptoms plus a radiographic infiltrate. Look for lobar consolidation with air bronchograms (lobar), patchy peribronchial opacities (broncho), or bilateral reticular/ground-glass opacities (interstitial).
• CT chest: more sensitive than radiography in early disease, neutropenia, or dehydration; used when the film is negative but suspicion is high, or to define cavitation, necrosis, or loculated fluid.

Step 2 — identify the organism (severity-driven)

• Sputum Gram stain and culture plus blood cultures: ATS/IDSA recommends these only in severe CAP, in patients being treated empirically for MRSA or Pseudomonas, or in prior infection/hospitalization with those organisms — not routinely in outpatients. Lancet-shaped gram-positive diplococci suggest pneumococcus.
• Urinary antigen testing: pneumococcal antigen and Legionella serogroup 1 antigen, recommended in severe CAP and in epidemiologic clusters/travel exposure. Legionella requires buffered charcoal yeast extract with cysteine and iron to grow.
• Nucleic acid amplification: influenza and SARS-CoV-2 PCR when circulating; *Mycoplasma*/*Chlamydia* PCR. Cold agglutinins are the classic but nonspecific Mycoplasma clue.
• Immunocompromised host: induced sputum or bronchoalveolar lavage with GMS/silver stain for Pneumocystis (cup- or boat-shaped cysts), markedly elevated LDH and serum beta-D-glucan; owl-eye inclusions for CMV.

Step 3 — score severity and decide site of care

• PSI/PORT: the 2019 ATS/IDSA guideline gives a conditional recommendation favoring PSI over CURB-65 for the admit-versus-discharge decision, based on its more extensive validation — not a strong or absolute preference.
• CURB-65: Confusion, Urea (BUN >19 mg/dL), RR ≥30, BP (SBP <90 or DBP ≤60), age ≥65; higher scores argue for admission.
• Scores supplement, not replace, judgment: ATS/IDSA advises combining the score with clinical assessment and social factors (ability to take oral drugs, home support, substance use, follow-up) rather than a single numeric cutoff.
• ATS/IDSA severe CAP criteria: one major (mechanical ventilation or vasopressor-requiring septic shock) or three minor criteria → ICU.
• Thoracentesis with Light's criteria for any moderate effusion; exudate with pH below roughly 7.2, low glucose, or organisms = complicated effusion requiring drainage.

Immediate stabilization

• Oxygen and hemodynamic support: target adequate saturation; for sepsis/septic shock give balanced crystalloid, obtain cultures, and start antibiotics within the first hour — an emergency, not a workup-first situation.

First-line empiric therapy (ATS/IDSA 2019 CAP)

• Outpatient, no comorbidities: aminopenicillin (amoxicillin) preferred; alternatives are doxycycline or a macrolide (azithromycin), the latter only where local pneumococcal macrolide resistance is <25% per the 2019 ATS/IDSA CAP guideline.
• Outpatient with comorbidities: beta-lactam + macrolide (amoxicillin-clavulanate or cefpodoxime plus azithromycin) or respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin).
• Inpatient, non-severe: beta-lactam + macrolide (ceftriaxone or ampicillin-sulbactam plus azithromycin), or respiratory fluoroquinolone alone.
• Severe/ICU: beta-lactam + macrolide or beta-lactam + fluoroquinolone; monotherapy with a macrolide is inadequate.

Escalation and pathogen-directed therapy

• MRSA coverage: vancomycin — dosed to a 24-hour AUC targeting AUC/MIC 400–600 per the 2020 IDSA/ASHP consensus — or linezolid; add only for prior MRSA respiratory isolation or validated local risk, then de-escalate on culture data.
• Pseudomonal coverage: antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime). ATS/IDSA 2019 retired the HCAP category; risk-factor-based coverage replaced it.
• Atypicals: Mycoplasma lacks a cell wall and Legionella is intracellular — beta-lactams fail; use a macrolide or fluoroquinolone.
• Influenza: oseltamivir for all hospitalized patients regardless of symptom duration.
• PCP: TMP-SMX, with adjunctive corticosteroids when room-air PaO₂ is below 70 mmHg or the A-a gradient exceeds 35 mmHg.

Definitive/procedural and duration

• Chest tube or VATS decortication for empyema or complicated parapneumonic effusion; antibiotics alone will not sterilize loculated pus.
• Minimum 5 days, extended until clinical stability; routine follow-up radiographs are not recommended, as clearance lags recovery.

Pleural and parenchymal

• Parapneumonic effusion → empyema: inflammatory capillary leak across visceral pleura, then bacterial invasion; signaled by persistent fever on appropriate antibiotics plus an enlarging effusion with low pH and low glucose. Empyema is a drainage emergency — antibiotics alone fail.
• Lung abscess / necrotizing pneumonia: tissue-destructive organisms (S. aureus, Klebsiella, anaerobes from aspiration) liquefy parenchyma; air-fluid level on upright film and foul-smelling sputum. Klebsiella classically causes an upper-lobe cavity with a bulging fissure.
• Organizing pneumonia / residual fibrosis: failed macrophage fibrinolysis during gray hepatization leaves intra-alveolar fibromyxoid plugs rather than restored architecture.
• Bronchiectasis: neutrophil elastase-mediated airway wall destruction after recurrent or necrotizing infection.

Systemic

• Bacteremia with metastatic seeding: pneumococcal bacteremia can seed distant sites; the classic Austrian triad is pneumococcal pneumonia + meningitis + endocarditis. Septic arthritis and brain abscess are additional (non-triad) metastatic sites. Emergency.
• Sepsis and septic shock: LPS/TLR4-driven vasoplegia; hypotension refractory to fluids. Emergency.
• ARDS from diffuse alveolar damage: hyaline membranes and refractory hypoxemia with bilateral infiltrates and non-cardiogenic edema. Emergency.
• SIADH with hyponatremia: cytokine-mediated ADH release, classically prominent in Legionella.
• Post-influenza bacterial superinfection: epithelial denudation and neuraminidase-exposed adhesion sites; biphasic fever with S. aureus or pneumococcus.

Treatment-related

• ***Clostridioides difficile* colitis**: flora disruption, especially after fluoroquinolones and broad beta-lactams; new watery diarrhea plus leukocytosis.
• Fluoroquinolone toxicities: tendinopathy/rupture, QT prolongation, CNS effects, aortic aneurysm/dissection risk.
• Vancomycin acute kidney injury: risk rises with supratherapeutic AUC exposure and with concurrent piperacillin-tazobactam; rising creatinine signals it.
• Linezolid: reversible thrombocytopenia and serotonin syndrome with serotonergic drugs.
• Macrolide QT prolongation and TMP-SMX hyperkalemia/marrow suppression.

• ***Rusty sputum* with lobar consolidation and air bronchograms** = Streptococcus pneumoniae; ***currant-jelly sputum* with an upper-lobe cavity and bulging fissure** = Klebsiella in an alcoholic or diabetic.
• Red versus gray hepatization: red = neutrophils plus intact RBCs and fibrin; gray = RBC breakdown with fibrinosuppurative debris and lysed neutrophils. Examiners test the order and the color-timing pair. Spread across the pores of Kohn is why the whole lobe consolidates.
• Single best next step for suspected pneumonia is the chest radiograph, not sputum culture, not CT, and not empiric antibiotics before any imaging in a stable outpatient.
• The association most tested: Mycoplasma has no cell wall, so beta-lactams are useless — cold agglutinin-positive teenager in a dorm or barracks gets a macrolide or doxycycline. The same logic covers intracellular Legionella.
• **Classic Legionella stem: pneumonia with diarrhea, hyponatremia (SIADH), confusion, and relative bradycardia, often with a water-source exposure → urinary antigen (detects serogroup 1 only), grows on charcoal yeast extract with cysteine and iron**.
• **The *Austrian triad* (pneumococcal pneumonia + meningitis + endocarditis) is the named triad to know for pneumococcus; septic arthritis and brain abscess are metastatic complications but are not** part of the triad.
• HIV with CD4 below 200, dyspnea out of proportion to exam, diffuse ground-glass opacities, high LDH = Pneumocystis; TMP-SMX, and add corticosteroids when room-air PaO₂ is under 70 mmHg or the A-a gradient exceeds 35 mmHg.
• Persistent fever despite appropriate antibiotics with an effusion → thoracentesis; a complicated effusion or empyema needs a chest tube, not a longer antibiotic course.
• Common distractors: the HCAP category was retired by the 2019 ATS/IDSA guideline; vancomycin is dosed to a 24-hour AUC (AUC/MIC 400–600), not to a 15–20 mcg/mL trough; and a routine follow-up chest film is not required because radiographic clearance lags clinical improvement by weeks.